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The comparative effectiveness of ﬁngolimod versus interferon beta/glatiramer acetate was assessed in a multicentre, observational,
prospectively acquired cohort study including 613 patients with relapsing multiple sclerosis discontinuing natalizumab in the Italian
iMedWeb registry. First, after natalizumab suspension, the relapse risk during the untreated wash-out period and during the course
of switch therapies was estimated through Poisson regression analyses in separated models. During the wash-out period an
increased risk of relapses was found in patients with a higher number of relapses before natalizumab treatment (incidence rate
ratio = 1.31, P = 0.0014) and in patients discontinuing natalizumab due to lack of efﬁcacy (incidence rate ratio = 2.33, P = 0.0288),
patient’s choice (incidence rate ratio = 2.18, P = 0.0064) and adverse events (incidence rate ratio = 2.09, P = 0.0084). The strongest
independent factors inﬂuencing the relapse risk after the start of switch therapies were a wash-out duration longer than 3 months
(incidence rate ratio = 1.78, P5 0.0001), the number of relapses experienced during and before natalizumab treatment (incidence
rate ratio = 1.61, P50.0001; incidence rate ratio = 1.13, P = 0.0118, respectively) and the presence of comorbidities (incidence rate
ratio = 1.4, P = 0.0097). Switching to ﬁngolimod was associated with a 64% reduction of the adjusted-risk for relapse in com-
parison with switching to interferon beta/glatiramer acetate (incidence rate ratio = 0.36, P5 0.0001). Secondly, patients who
switched to ﬁngolimod or to interferon beta/glatiramer acetate were propensity score-matched on a 1-to-1 basis at the switching
date. In the propensity score-matched sample a Poisson model showed a signiﬁcant lower incidence of relapses in patients treated
with ﬁngolimod in comparison with those treated with interferon beta/glatiramer acetate (incidence rate ratio = 0.52, P = 0.0003)
during a 12-month follow-up. The cumulative probability of a ﬁrst relapse after the treatment switch was signiﬁcantly lower in
patients receiving ﬁngolimod than in those receiving interferon beta/glatiramer acetate (P = 0.028). The robustness of this result
was also conﬁrmed by sensitivity analyses in subgroups with different wash-out durations (less or more than 3 months). Time to 3-
month conﬁrmed disability progression was not signiﬁcantly different between the two groups (Hazard ratio = 0.58; P = 0.1931).
Our results indicate a superiority of ﬁngolimod in comparison to interferon beta/glatiramer acetate in controlling disease reacti-
vation after natalizumab discontinuation in the real life setting.
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Introduction
The handling of treatment sequencing in relapsing multiple
sclerosis patients who must discontinue natalizumab for
efﬁcacy or tolerability reasons or because they have a
high risk of developing progressive multifocal leukoence-
phalopathy, is one of the main issues in patient manage-
ment that neurologists are facing today. After natalizumab
discontinuation, there is a risk of disease reactivation
(Killestein et al., 2010; West et al., 2010; Borriello et al.,
2011, 2012; Havla et al., 2011; Kaufman et al., 2011;
Kerbrat et al., 2011; Magraner et al., 2011; O’Connor
et al., 2011; Rossi et al., 2013; Cohen et al., 2014)
which correlates with the wash-out duration and disease
activity before (O’Connor et al., 2011) and during
(Jokubaitis et al., 2014) natalizumab treatment. The risk
seems to be higher after 3 months of wash-out, with a
peak between 4 and 7 months (O’Connor et al., 2011;
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Cohen et al., 2014), but a high rate of recurrence of clinical
activity has been demonstrated as early as 4–8 weeks after
the last natalizumab infusion in a more recent randomized
study (Fox et al., 2014).
Switching from natalizumab to ﬁrst-line Betaferon

,
Betaseron

, Rebif

, Avonex

, Copaxone

or Extavia

(BRACE) or ﬁngolimod may be reasonable options for
preventing disease reactivation, but results of published
studies are not conclusive and often discordant (Stuve
et al., 2009; Havla et al., 2011, 2013; Magraner et al.,
2011; O’Connor et al., 2011; Borriello et al., 2012;
Centonze et al., 2012; Rinaldi et al., 2012; Laroni et al.,
2013; Rossi et al., 2013; Sempere et al., 2013; Clerico
et al., 2014; Cohen et al., 2014; Fox et al., 2014;
Jokubaitis et al., 2014).
The randomized Restore study (Fox et al., 2014) and the
Italian prospective spontaneous observational study TY-
STOP (Clerico et al., 2014) have proved the superiority
of continuing natalizumab in comparison with its
interruption despite switching to ﬁrst-line BRACE or
methylprednisolone.
The effect of ﬁngolimod in preventing disease reactiva-
tion after natalizumab discontinuation has been evalu-
ated by a number of small size observational studies
(Rinaldi et al., 2012; Havla et al., 2013; Laroni et al.,
2013; Sempere et al., 2013). Two of them (Havla et al.,
2013; Laroni et al., 2013) suggested patients who
switched to ﬁngolimod within 6 months after natalizu-
mab had reduced annualized relapse rates compared with
those who remained untreated or who switched to intra-
muscular interferon beta (IFNb)-1a or glatiramer acetate,
whereas two other studies (Rinaldi et al., 2012; Sempere
et al., 2013) reported increased severe relapses in patients
switching to ﬁngolimod during the 3–4 months after
natalizumab discontinuation. Two more recent and
larger observational studies (Cohen et al., 2014;
Jokubaitis et al., 2014) provided results in favour of dis-
ease activity stabilization in patients with an early switch
to ﬁngolimod after natalizumab. Although ﬁngolimod
seems to be the most attractive option available so far,
no direct comparative effectiveness study of ﬁngolimod
versus placebo or versus BRACE has yet been carried
out. Hence to date, there are no conclusive guidelines
nor is there any consensus underpinning practice as re-
gards the best currently available treatment option and
the safest wash-out duration for relapse risk reduction
after natalizumab suspension.
In a large unselected cohort of prospectively-followed
Italian patients with relapsing-remitting multiple sclerosis
discontinuing natalizumab therapy, we directly compared
the effectiveness of ﬁngolimod versus BRACE in control-
ling clinical disease reactivation after natalizumab suspen-
sion. Moreover, we evaluated clinical and demographic
factors inﬂuencing the relapse risk during both the un-
treated wash-out period and the course of treatment
switch.
Materials and methods
Database and study population
This was a large, multicentre, observational, prospectively
acquired cohort study. Longitudinal data from 26086 patients
from 45 Italian multiple sclerosis centres were extracted from
the iMedWeb registry in December 2013. Inclusion criteria for
the subsequent analysis comprised patients with a diagnosis of
multiple sclerosis (Polman et al., 2011), at least six natalizu-
mab infusions before discontinuation, and the availability of a
minimal data set consisting of: sex, date of birth, date of mul-
tiple sclerosis onset, dates of clinical relapses occurring in the
year preceding natalizumab initiation, during natalizumab
treatment and after natalizumab suspension, immunomodulant
and/or immunosuppressive therapies before natalizumab treat-
ment (yes/no), reasons for natalizumab discontinuation, dates
of start and type of treatment switch after natalizumab,
Expanded Disability Status Scale (EDSS) score recorded at
the time of the ﬁrst and last natalizumab infusions, and
during the treatment switch. Any invalid or inconsistent entries
were identiﬁed and excluded in a series of automated ﬁltering
steps. Patients were censored at the end of follow-up. Patients
who stopped natalizumab treatment owing to the occurrence
of progressive multifocal leukoencephalopathy were excluded
from the analysis. The ﬁnal population entering the analysis
included 613 patients from 24 Italian sites (Fig. 1).
During the post-natalizumab suspension follow-up, the deci-
sion on whether, how, and when to restart alternative treat-
ment was the responsibility of the treating neurologist at each
participating centre. Of the total cohort of 613 patients, 433
patients received at least one disease-modifying drug prescrip-
tion during the follow-up. The time interval between natalizu-
mab cessation and switching to another therapy or the end of
follow-up period for patients who did not start other therapies
was considered as an untreated wash-out period. This made it
possible to estimate the risk of relapse during the wash-out
period in the entire study population (n = 613). The factors
inﬂuencing relapse risk after starting switching therapies were
evaluated in 433 patients, 135 of whom switched to ﬁngoli-
mod and 298 to BRACE (n = 160 any formulation of IFNb,
n = 138 glatiramer acetate) (Fig. 1). The comparative effective-
ness of ﬁngolimod versus BRACE for relapse risk was assessed
in propensity score-matched groups. Finally, the comparative
effect on disability progression was also estimated in propen-
sity score-matched patients. Conﬁrmed disability progression
was deﬁned as53-month conﬁrmed increase of 51.0 point
EDSS score compared to the EDDS value at the time of the
switch in therapy
Statistical analyses
In descriptive analyses, continuous variables were summarized
as mean and standard deviation (SD) or median and interquar-
tile range (IQR), and categorical variables were expressed as
percentages. The risk of relapses during the untreated wash-
out period and after switching therapy was estimated through
a Poisson regression analysis in separated models. Incidence
rates were expressed as number of events/100 patients/month
and the risk of relapses was reported as incidence rate ratio
(IRR).
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To evaluate the risk of relapses during the untreated wash-
out period the following covariates, evaluated at the time of
the last infusion of natalizumab, were included in the model:
sex, age, disease duration, EDSS, comorbidity (thyroid dys-
function/allergy/headache/other) (yes/no), immunomodulant
exposure prior to natalizumab (yes/no), immunosuppressive
exposure prior to natalizumab (yes/no), number of relapses
in the year before natalizumab and during natalizumab,
number of natalizumab infusions and reasons for natalizumab
suspension (progressive multifocal leukoencephalopathy con-
cern, pregnancy, adverse event, patient’s choice or lack of ef-
ﬁcacy of the natalizumab treatment).
The factors inﬂuencing the relapse risk after starting switch-
ing therapies were then estimated including the following cov-
ariates, evaluated at the time of the switch in therapy, in the
model: sex, age, disease duration, EDSS, comorbidity (thyroid
dysfunction/allergy/headache/other) (yes/no), immunomodulant
exposure prior to natalizumab (yes/no), immunosuppressive
exposure prior to natalizumab (yes/no), number of relapses
in the year before natalizumab, during natalizumab and
during the wash-out period, number of natalizumab infusions,
switching therapy (ﬁngolimod/BRACE), wash-out length (0-3
versus43 months). To assess the effect of different durations
of the untreated wash-out on treatment response, we applied a
wash-out cut-off of 3 months.
To compare the effectiveness of switching therapies on clinical
disease reactivation we evaluated the relapse risk in two groups
of patients: those who switched to ﬁngolimod and those who
switched to BRACE. Furthermore, to allow for an unbiased
comparison, these patients were propensity score-matched on
a one-to-one basis, at the time of the switch (Parsons et al.,
2004; Yanovitzky et al., 2005). A ﬁve-to-one greedy matching
algorithm was used to identify a unique matched BRACE-trea-
ted patient for each ﬁngolimod-treated patient according to the
propensity score. Adequacy of balance for the covariates in the
matched sample was assessed via the standardized mean differ-
ence between the two groups, considering differences of 510%
as a good balance (Austin et al., 2007). Overlapping of propen-
sity score between the two groups was also checked. The pro-
pensity score was calculated by a logistic regression model using
the probability of receiving ﬁngolimod as a dependent variable
and including the following covariates at the time of the treat-
ment switch: sex, age, disease duration, EDSS, comorbidity (thy-
roid dysfunction/allergy/headache/other–yes/no), previous
immunomodulant exposure (yes/no), previous immunosuppres-
sive exposure (yes/no), number of natalizumab infusions, occur-
rence of relapse (yes/no) before and during natalizumab and
during the wash-out period. In the matched sample, a Poisson
model was used to allow a comparison between patients treated
with ﬁngolimod or BRACE in terms of the risk of relapses after
the treatment switch. Since the wash-out duration was markedly
different between patients switching to ﬁngolimod and those
receiving BRACE, this covariate was not included in the pro-
pensity score procedure, but ad hoc sensitivity analyses were
performed: propensity score matching (including the same cov-
ariates) was applied to two subgroups of patients, those who
received ﬁngolimod or BRACE within 3 months, and those with
a wash-out period of 43 months after natalizumab discontinu-
ation, the Poisson models were performed to estimate the inci-
dence of relapses in both subgroups. Probabilities of relapses
during the wash-out period and after switching to ﬁngolimod
or BRACE were calculated using the Kaplan-Meier method.
Comparison of the relapse risk between patients treated with
ﬁngolimod or BRACE was performed using the log-rank test.
Figure 1 Flow-chart showing patients selection. FIN = fingolimod; PML = progressive multifocal leukoencephalopathy.
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Comparison of time to conﬁrmed disability progression was
obtained by a time-to-event Cox regression model. P-values
were 2-sided, and values 50.05 were considered to be statistic-
ally signiﬁcant. All statistical analyses were performed using SAS
version 9.3 (SAS Institute Inc.).
Results
At the time of data extraction 1394 patients had received at
least six infusions of natalizumab, and 616 of 1394 pa-
tients had deﬁnitively stopped the treatment. Three patients
were excluded as the reason for discontinuation was diag-
nosis of progressive multifocal leukoencephalopathy
(Fig. 1). The demographic and clinical characteristics of
the whole study population are shown in Table 1.
Patients had received a mean of 23.59 (11.10) natalizu-
mab infusions. The mean annualized relapse rates were sig-
niﬁcantly reduced at the time when natalizumab was
stopped (0.35  1.27) in comparison with annualized re-
lapse rates in the year before natalizumab (1.21  1.06);
the mean EDSS score remained stable during natalizumab
treatment (3.53  1.69 at natalizumab start versus
3.54  1.57 at natalizumab stop, P = not signiﬁcant). The
main reasons for discontinuation were: progressive multi-
focal leukoencephalopathy concerns in 58.56%, adverse
events in 18.43%, patient’s choice in 12.23%, lack of efﬁ-
cacy in 6.69% and conﬁrmed pregnancy in 4.08% of pa-
tients. One hundred and nineteen patients (19.4%)
experienced at least one clinical relapse after stopping nata-
lizumab during the untreated wash-out period. The median
of untreated wash-out duration was 2.5 (q1–q3 = 1–5.3)
months for the total population and 5.1 (q1–q3 = 3.5–
10.5) months for patients who switched to ﬁngolimod
and 1.4 (q1–q3 = 0.9–3.1) months in patients who switched
to BRACE.
The Poisson regression analysis (Table 2) demonstrated
that the clinical disease activity before natalizumab treatment
was associated with an increased risk in disease reactivation
during the wash-out period (IRR = 1.31, P = 0.0014).
Furthermore, a higher risk of relapse during the wash-out
was found in patients discontinuing natalizumab due to lack
of efﬁcacy (IRR = 2.33, P = 0.0288), patient’s choice
(IRR = 2.18, P = 0.0064) and adverse events (IRR = 2.09,
P = 0.0084) in comparison with those stopping natalizumab
due to progressive multifocal leukoencephalopathy concerns.
Figure 2A shows the cumulative probability of the ﬁrst
relapse during the untreated wash-out period after natali-
zumab suspension. The cumulative probability was 0.25%
in the ﬁrst month, it grew 3-fold in the second and third
months (1.08–1.75%) and more than 10 times thereafter
(4–6%). At 12 months after natalizumab discontinuation,
22.3% of patients presented at least one relapse.
The Poisson model, which included the covariates evalu-
ated at the time of switching, revealed that the strongest
independent factors inﬂuencing the risk of relapse after the
start of a new therapy were a wash-out duration longer
than 3 months (IRR = 1.78, P5 0.0001), the number of
relapses experienced during and before natalizumab treat-
ment (IRR = 1.61, P5 0.0001; IRR = 1.13, P = 0.0118, re-
spectively), and the presence of comorbidities (IRR = 1.4,
P = 0.0097). Switching to ﬁngolimod was associated with
a 64% reduction in the risk of relapse in comparison to
switching to BRACE (IRR = 0.36, P5 0.0001). In addition,
increasing age and disease duration, at the switch,
were associated with a reduction in risk of relapses
(IRR = 0.98, P = 0.0111; IRR = 0.98, P = 0.0444, respect-
ively), whereas for each infusion of natalizumab there
was an increase of 1% in the risk of relapse during the
switching treatment (IRR = 1.01, P = 0.0439). (Table 3)
Table 4 presents the clinical and demographic character-
istics of the two groups of patients receiving ﬁngolimod or
BRACE treatments after natalizumab suspension, at the
time of the treatment switch. Before propensity score
matching, there were signiﬁcant differences between the
two patients groups for all the covariates, except for sex,
EDSS, number of patients with relapse during natalizumab,
number of patients with previous immunomodulant expos-
ure and with previous immunosuppressive exposure.
After the propensity score matching, the two groups were
perfectly balanced for all the covariates (Table 4). Because
of no overlapping propensity score, 20.74% of patients
receiving ﬁngolimod were excluded from the analyses.
This is considered an acceptable percentage of no over-
lapped cases in propensity score models (Austin et al.,
2007). The matched sample was 107 patients for both
groups.
The Poisson model performed in the propensity score-
matched groups showed a signiﬁcantly lower incidence of
relapses in patients treated with ﬁngolimod in comparison
with patients treated with BRACE (IRR = 0.52, P = 0.0003)
(Table 5).
The cumulative probability of a ﬁrst relapse after the
treatment switch was signiﬁcantly lower in patients receiv-
ing ﬁngolimod than in those receiving BRACE (P = 0.028)
(Fig. 2B).
The cumulative probability of a ﬁrst relapse during the
ﬁrst year of post-switching follow-up in patients treated
with ﬁngolimod versus those treated with BRACE was
6.10% versus 9.89% at the end of the fourth month,
13.49% versus 20.13% at the end of the eighth month
and 15.01% versus 26.84% at 12 months.
Sensitivity analyses in 25 pairs of matched patients with a
wash-out duration between 0 and 3 months and in 73 pairs
of matched patients with wash-out duration over 3 months
conﬁrmed the lower risk of relapses in patients switching
to ﬁngolimod in comparison with BRACE (IRR = 0.53,
P = 0.0363, IRR = 0.41, P = 0.0013, respectively) (Table 6).
A conﬁrmed 1.0 point increase of the EDSS score was
reached by 22.5% of patients receiving BRACE, and by
11.4% of those receiving ﬁngolimod (P = 0.06). However
the different rate of conﬁrmed disability progression
between the two groups of patients did not reach a statis-
tical signiﬁcance in the Cox model (Hazard ratio = 0.58,
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95% conﬁdence interval = 0.26–1.31, reference = BRACE;
P = 0.1931).
Discussion
To date, there are no head-to-head randomized controlled
trials or large observational comparative effectiveness stu-
dies indicating what is the optimal treatment strategy to
prevent the consistently shown risk of disease reactivation
for patients who discontinue natalizumab treatment for ef-
ﬁcacy or safety issues (Stuve et al., 2009; Killestein et al.,
2010; West et al., 2010; Borriello et al., 2011, 2012; Havla
et al., 2011; Kaufman et al., 2011; Kerbrat et al., 2011;
Magraner et al., 2011; O’Connor et al., 2011; Rinaldi
et al., 2012; Rossi et al., 2013).
First, in this study we evaluated clinical and demographic
factors inﬂuencing the relapse risk during the untreated
wash-out period after stopping natalizumab. We conﬁrmed
ﬁndings of previous studies (O’Connor et al., 2011; Cohen
Table 2 Poisson regression analysis: risk of relapses during the wash-out period (n = 613)
Variable Category IR (95% IR CI) IRR (95% IRR CI) P
Sex Male 4.87 (2.83–8.38) 1.1 (0.73–1.65) 0.655
Female 4.44 (2.87–6.87) 1
Age at NTZ stop 0.99 (0.97–1.02) 0.486
Disease duration at NTZ stop 1.02 (0.99–1.06) 0.193
EDSS at NTZ stop 0.88 (0.78–1.00) 0.058
Comorbidity Yes 3.58 (1.85–6.93) 0,59 (0.33–1.06) 0.080
No 6.04 (4.18–8.72) 1 .
Previous IM exposure Yes 4.29 (2.98–6.17) 0.85 (0.48–1.51) 0.581
No 5.04 (2.61–9.74) 1 .
Previous IS exposure Yes 4.52 (2.61–7.85) 0.95 (0.61–1.46) 0.805
No 4.78 (3.09–7.40) 1 .
Relapses in the year before NTZ, n 1.31 (1.11–1.54) 0.001
n of relapses during NTZ 1.04 (0.85–1.28) 0.706
NTZ infusions, n 1.02 (1.00–1.03) 0.093
Main reasons of discontinuation Adverse event 5.57 (3.23–9.62) 2.09 (1.21–3.62) 0.008
Patient’s choice 5.79 (3.31–10.10) 2.18 (1.25–3.79) 0.006
Lack of efficacy 6.2 (2.94–13.06) 2.33 (1.09–4.97) 0.029
Pregnancy 4.09 (1.90–8.81) 1.54 (0.76–3.12) 0.234
PML concern 2.66 (1.65–4.29) 1 .
IR = incidence rate for 100 person/month; NTZ = natalizumab; PML = progressive multifocal leukoencephalopathy; IM = immunomodulant; IS = immunosuppressant; CI =
confidence interval.
Table 1 Demographic and clinical baseline characteristics of the entire study population
Variable Value
Sex (female/male) 439/174
Age at NTZ stop, mean (SD), years 37.5 (9.0)
Disease duration at NTZ stop, mean (SD), years 12.1 (6.9)
EDSS score at NTZ start, mean (SD); median (min–max) 3.5 (1.6); 3.5 (0–8)
EDSS score at NTZ stop, mean (SD); median (min–max) 3.5 (1.7); 3.5 (0–8)
n of NTZ infusions, mean (SD); median (min–max) 23.6 (11.1); 24 (6–84)
ARR in the year before NTZ, mean (SD); median (min–max) 1.2 (1.1); 1 (0–6)
ARR during NTZ, mean (SD); median (min–max) 0.3 (1.3); 0 (0–7)
IM exposure prior to NTZ, n (%) Yes 539 (87.9)
No 74 (12.1)
IS exposure prior to NTZ, n (%) Yes 129 (21)
No 484 (79)
Comorbidity, n (%) (thyroid dysfunction/allergy/headache/other) Yes 84 (13.7)
No 529 (86.3)
Main reasons for discontinuation, n (%) PML concern 359 (58.6)
Adverse event 113 (18.4)
Patient’s choice 75 (12.2)
Lack of efficacy 41 (6.7)
Pregnancy 25 (4.1)
ARR = annualized relapse rate; NTZ = natalizumab; IM = immunomodulant; IS = immunosuppressant; PML = progressive multifocal leukoencephalopathy.
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et al., 2014; Fox et al., 2014) showing a higher risk of
relapse in patients discontinuing natalizumab due to lack
of efﬁcacy or the occurrence of adverse events and in pa-
tients with high disease activity before natalizumab. In our
cohort, the cumulative probability of a ﬁrst relapse was less
than 0.5% during the ﬁrst month, but it grew 3-fold in the
second and third months and more than 10 times there-
after. This is in line with the results of the randomized
Restore study (Fox et al., 2014) demonstrating that in pa-
tients assigned to the placebo arm (42 patients), after
Figure 2 Cumulative probabilities of a first relapse. (A) Cumulative probability of a first relapse during the untreated wash-out period
after natalizumab discontinuation. (B) Cumulative probability of a first relapse after the treatment switch.
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natalizumab interruption, the total proportion of patients
with a relapse was 17%, but most of the relapses occurred
after the fourth month. In addition these ﬁndings conﬁrm
the results of a large observational study reporting an
increasing risk of relapse after natalizumab discontinuation,
with a peak after 4 months (O’Connor et al., 2011).
Second, using a Poisson model, performed at the time of
switching therapies, we demonstrated that younger patients
with shorter disease duration and comorbidities are more at
risk of relapse after natalizumab suspension. Moreover, we
conﬁrmed that a high (O’Connor et al., 2011; Cohen et al.,
2014; Fox et al., 2014) disease activity before natalizumab
and/or during natalizumab and a wash-out duration of 43
months are strong independent factors inﬂuencing the
risk of relapse, even after the start of a new therapy.
Accordingly, Jokubaitis et al. (2014) found that patients
with relapses during the 6 months before ﬁngolimod start
and patients with a wash-out duration of 2–4 months had
Table 3 Poisson regression analysis: risk of relapses after the treatment switch (n = 433)
Variable Category IR (95% IR CI) IRR (95% IRR CI) P
Sex Male 6 (4.32–8.24) 0.97 (0.74–1.27) 0.828
Female 6.2 (4.75–7.95) 1
Age at switch 0.98 (0.97–1.00) 0.011
Disease duration at switch 0.98 (0.96–1.00) 0.044
EDSS at switch 0.94 (0.88–1.01) 0.097
Comorbidity Yes 7.2 (5.19–9.88) 1.4 (1.09–1.80) 0.01
No 5.1 (3.98–6.58) 1
Previous IM exposure Yes 6.5 (5.27–8.12) 1.17 (0.81–1.68) 0.408
No 5.6 (3.78–8.30) 1
Previous IS exposure Yes 6.8 (4.87–9.47) 1.26 (0.96–1.65) 0.099
No 5.4 (4.22–6.91) 1
Relapses in the year before NTZ, n 1.13 (1.03–1.25) 0.012
Relapses during NTZ, n 1.61 (1.46–1.78) 50.0001
Relapses during the wash-out n 0.99 (0.79–1.22) 0.898
NTZ infusions, n 1.01 (1.00–1.02) 0.044
Wash-out length 43 months 8.1 (6.09–10.74) 1.78 (1.39–2.30) 50.0001
0–3 months 4.5 (3.38–6.08) 1
Treatment FIN 3.7 (2.49–5.33) 0.36 (0.25–0.52) 50.0001
BRACE 10 (7.97–12.68) 1
IR = incidence rate for 100 person/month; NTZ = natalizumab; PML = progressive multifocal leukoencephalopathy; IM = Immunomodulant; IS = Immunosuppressant; FIN =
fingolimod.
Table 4 Patients characteristics before and after propensity-score matching
Before propensity-score matching After propensity-score matching
Variable BRACE FIN P* Standardized
difference (%)
BRACE FIN P* Standardized
difference (%)
n 298 135 107 107
Age at switch mean (SD), years 37.2 (8.8) 39.7 (9.6) 0.011 27.1 38.8 (8.7) 38.6 (9.1) 0.959 1.1
Sex, male (%) 86 (28.9) 38 (28.1) 0.880 1.6 30 (28.0) 34 (31.8) 0.550 8.2
Disease duration at switch
mean (SD), years
11.9 (7.1) 13.4 (6.5) 0.011 21.8 12.2 (6.8) 12.9 (6.5) 0.375 10.0
EDSS at switch mean (SD) 3.5 (1.7) 3.7 (1.9) 0.1 16.1 3.6 (1.7) 3.8 (1.8) 0.338 12.3
Patients with comorbidity, n (%) 57 (19.1) 14 (10.4) 0.023 24.9 14 (13.1) 13 (12.1) 0.837 2.8
Patients with previous IM treatment, n (%) 267 (89.6) 120 (88.9) 0.825 2.3 92 (85.3) 93 (86.9) 0.842 2.7
Patients with previous IS treatment, n (%) 61 (20.5) 27 (20.0) 0.910 1.2 20 (18.7) 21 (19.6) 0.862 2.4
NTZ infusions, n mean (SD) 19.4 (11.5) 26.4 (14.1) 50.0001 54.3 22.4 (11.0) 23.2 (12.1) 0.571 7.7
Patients who relapsed in the
year prior to NTZ, n (%)
242 (81.2) 84 (62.2) 50.0001 43.1 71 (66.4) 73 (68.2) 0.771 3.9
Patients who relapsed during NTZ, n (%) 74 (24.8) 43 (31.8) 0.128 15.6 28 (26.2) 31 (29.0) 0.646 6.3
Patients who relapsed during
the wash-out, n (%)
39 (13.1) 44 (32.6) 50.0001 47.8 28 (26.2) 26 (24.3) 0.753 4.3
*Mann–Whitney U-test for continuous variables and 2 statistic for categorical variables.
FIN = fingolimod; IM = immunomodulant; IS = Immunosuppressant; NTZ = natalizumab; SD = standard deviation.
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1.6 and 2.12 times increased risk of a post-switching re-
lapse, respectively, in comparison to patients without pre-
vious relapses and no treatment gap.
All of these results taken together suggest that more ag-
gressive treatments should be considered early in the dis-
ease course for patients with a very active presentation
from the disease onset, and that a wash-out duration last-
ing more than 1–3 months after natalizumab cessation is
no longer acceptable in clinical practice.
Most importantly, we demonstrate that, after the adjust-
ment for all the covariates, switching to ﬁngolimod was
associated with a 64% reduction in the risk of relapse in
comparison to switching to BRACE. Moreover, the results
of the Poisson analysis, performed after propensity score
matching, strongly conﬁrmed in the two quasi-randomized
groups, that ﬁngolimod is more effective than BRACE in
reducing the incidence of disease reactivation and the cu-
mulative probability of a ﬁrst relapse after natalizumab
suspension. In this cohort, 6.10% of patients on ﬁngolimod
had a ﬁrst relapse within the ﬁrst 4 months of treatment,
13.49% at 8 months and 15.01% at 12 months of follow-
up, whereas the percentages of patients with a ﬁrst relapse
after switching to BRACE were 9.89%, 20.13% and
26.84%, at the same time points, respectively. The super-
iority of ﬁngolimod versus BRACE was further conﬁrmed,
by sensitivity analyses, in subgroups of patients with differ-
ent wash-out durations (less than or more than 3 months)
and with consequent different relapse risks. Our study con-
ﬁrms the results of a previous head to head randomized
controlled trial (Cohen et al., 2013) designed to compare
the efﬁcacy of ﬁngolimod versus intramuscular IFNb-1a in
patients with a very active form of multiple sclerosis, des-
pite treatment with IFNb in the year before the study, and
those from other randomized controlled trials (Fox et al.,
2014) and observational studies (Havla et al., 2013; Laroni
et al., 2013; Rossi et al., 2013; Sempere et al., 2013;
Clerico et al., 2014; Cohen et al., 2014; Jokubaitis et al.,
2014) aimed to, independently, evaluate the efﬁcacy of ﬁn-
golimod or BRACE in controlling the disease reactivation
after natalizumab suspension. The 1-year randomized con-
trolled trial (Cohen et al., 2013) showed that ﬁngolimod
signiﬁcantly reduced the annualized relapse rates by 52%,
compared with IFNb-1a. Two studies, one randomized and
partially controlled (Fox et al., 2014) and one observa-
tional (Clerico et al., 2014), analysed multiple sclerosis
disease recurrence after natalizumab withdrawal in
subpopulations of patients (n = 175 and n = 124, respect-
ively) with restricted inclusion criteria (patients stable on
natalizumab with no clinical or MRI evidence of disease
activity) during a follow-up of 6 months and 12 months,
respectively. Although these two studies were not designed
to determine whether one treatment was better than an-
other, as their main objective was to determine whether
multiple sclerosis worsened after stopping natalizumab,
they did demonstrate that ﬁrst-line BRACE are not able
to abolish post-natalizumab disease reactivation (Clerico
et al., 2014; Fox et al., 2014). Some small size observa-
tional studies (Havla et al., 2013; Laroni et al., 2013)
found that patients who switched to ﬁngolimod within 6
months of natalizumab discontinuation had reduced
annualized relapse rates compared with those who re-
mained untreated or switched to intramuscular IFNb-1a
or glatiramer acetate. Larger size (Cohen et al., 2014;
Jokubaitis et al., 2014) observational studies suggested a
stabilization of disease reactivation in patients who
switched to ﬁngolimod after natalizumab. The French
ENIGM study (Cohen et al., 2014), which gathered data
from 333 patients with multiple sclerosis who switched
from natalizumab to ﬁngolimod, after a mean wash-out
duration of 17 weeks, found that 20% of them relapsed
Table 6 Sensitivity analysis: Poisson regression analysis performed in the two groups of propensity-score matched
patients stratified by wash-out duration (0–3 months;43 months)
WO duration Treatment n n of events Person-Year IR (95% IR CI) IRR (95% IRR CI) P
0–3 months Fingolimod 25 18 46.55 38.70 (24.36–61.37) 0.53(0.30–0.94) 0.036
BRACE 25 31 42.35 73.20 (51.48–104.10) 1
43 months Fingolimod 73 17 733.28 2.32 (1.44–3.73) 0.41 (0.24–0.69) 0.001
BRACE 73 60 1048.23 5.72 (4.44–7.37) 1
WO = wash-out; n = number; IR = Incidence for 100 person/month; IRR = Incidence Rate Ratio; CI = Confidence Intervals.
Table 5 Poisson regression analysis: incidence of relapse after switch in propensity score-matched patients
Treatment n n of events Person-years IR (95% IR CI) IRR (95% IRR CI) P
Fingolimod 107 46 890.70 5.16 (3.87–6.89) 0.52 (0.37–0.74) 0.0003
BRACE 107 114 1154.99 9.87 (8.21–11.86) 1
IR = Incidence for 100 person/month.
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during the ﬁrst 6 months of ﬁngolimod therapy, but
the occurrence of relapse during the wash-out was the
only statistically signiﬁcant prognostic factor for relapse
during ﬁngolimod therapy. Jokubaitis et al. (2014) from
the MSBase platform found a small increase in annualized
relapse rates on ﬁngolimod relative to natalizumab
treatment in patients switching from natalizumab to
ﬁngolimod.
Comi et al. (2014), in a post hoc analysis of an open
label, phase 3b study (FIRST), demonstrated that ﬁngoli-
mod was able to reduce the proportion of patients experi-
encing relapses after natalizumab but that timing of
treatment initiation is critical for achieving an optimal
effect.
All these previous studies consistently emphasized that
ﬁngolimod has the potential to reduce disease reactivation
after natalizumab withdrawal, but this is the ﬁrst compara-
tive effectiveness study of ﬁngolimod versus BRACE con-
ﬁrming the superiority of ﬁngolimod versus BRACE in a
real-world setting.
In this study, as expected in a follow-up lasting 12
months, the rate of conﬁrmed disability progression was
not signiﬁcantly different between the two groups although
the conﬁrmed disability progression events were found in
11.4% of patients receiving ﬁngolimod and in 22.5% of
patients receiving BRACE.
Some limitations of this study deserve discussion. First,
although we have applied sophisticated statistical analysis
to reduce possible confounders that could have biased the
results, the lack of randomization and blinded evaluation of
outcomes remain insurmountable limits common to all ob-
servational studies. Second, we only evaluated clinical out-
comes, and did not systematically collect radiologic data.
The latter is the main limitation of this study, but since the
data from randomized controlled trials (Cohen et al., 2010,
2013) consistently provided evidence of a superior efﬁcacy
of ﬁngolimod over IFNb in improving MRI outcomes
(number of new Gd-enhancing lesions, active T2 lesions,
and the rate of brain volume loss) across different sub-
groups of patients with relapsing-remitting multiple scler-
osis, including those with high disease activity, the lack of
this information might be only responsible for an under-
estimation of the major effectiveness of ﬁngolimod in com-
parison to BRACE. In conclusion, our ﬁndings conﬁrm the
occurrence of a clinical disease reactivation after natalizu-
mab suspension, mainly in patients with multiple sclerosis
experiencing a previous high disease activity before and
during natalizumab treatment, and the importance of estab-
lishing an alternative treatment, promptly, within 30 days,
after the suspension. However, the most relevant ﬁnding of
this prospective comparative study is the demonstration
that ﬁngolimod, among currently available disease-
modifying drugs, is the best treatment choice for control-
ling this risk. Comparisons of ﬁngolimod with newer
available oral and injectable therapies in the clinical prac-
tice setting are eagerly awaited.
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